A Pharmaceutical Game-Changer
Auxesis' Business Idea
AUXESIS DEVELOPS, BASED ON ITS OWN PATENT, INOVATIVE MEDECINES THAT QUICKLY REMOVE PAIN AND IRRITATION ON THE SKIN OF BOTH HUMANS AND ANIMALS AND THAT ARE EASILY ACCESSIBLE TO CONSUMERS AND VARIOUS PROFESSIONAL GROUPS.
AUXESIS PHARMA HOLDING AB (publ), hereafter “Auxesis”, is a public company focused on the development of human and animal pharmaceuticals in the category of local skin pain and irritation.
Unique Innovation That Blocks The Pain
After years of research and thousands of trials, Auxesis, together with Professor Moustapha Hassan and his team at Karolinska Institutet, Stockholm, have managed to do what no one else has done before; stabilise Acetylsalicylic Acid (ASA) in liquid form, allowing it to be applied to the skin.
Currently, there are two trademarks registered globally; ASA.P® and CoxyPet®.
ASA.P® is the first over-the-counter consumer product that quickly removes pain and irritation on the skin.
Over-The-Counter Consumer Product
ASA.P® is an over-the-counter medicine for human use to treat pain and irritation on the skin caused by insect bites, jellyfish, stinging nettles and other allergenic plants, minor burns, sunburn, rashes and eczema.
ASA.P® is the first over-the-counter consumer product that quickly removes pain and irritation on the skin:
Vision
TO REDEFINE THE PHARMACEUTICAL CATEGORY OF PAIN AND SKIN IRRITATION WITH SCIENCE AS THE DOUNDATION
Acetylsalicylic acid (ASA) is one of the most well-known substances for pain relief and has been used in pharmaceuticals since the late 19th century, including in Treo, Bamyl, and Aspirin.
After years of research and thousands of trials, Auxesis, together with Professor Moustapha Hassan and his team, has achieved what no one else has before: stabilizing ASA in liquid form.
With ASA in liquid form, there are new possibilities to develop entirely new formulations that can be easily applied directly to the skin, eliminating pain or irritation within minutes by blocking the pain signal to the brain. By adding other pharmaceutically active substances, the effect is maintained until the body has healed itself. Studies indicate that ASA.P remains on the skin and does not enter the bloodstream.
Based on proprietary patents, Auxesis is the first to develop innovative and accessible pharmaceuticals that not only relieve but rapidly eliminate pain and irritation on the skin.
